Recruitment is expected to begin later this year, with plans for geographic expansion into the UK and the US.

Diffuse cutaneous systemic sclerosis (“dcSSc”) is a rare, progressive autoimmune disease characterized by immune activation, vasculopathy and fibrosis affecting the skin and internal organs, including ...

Medicus Pharma (NASDAQ:MDCX) said on Thursday that its experimental microneedle-based therapy showed encouraging efficacy in ...

FDA authorization under an IND permits first-in-human phase I/II testing of SVT-001 in familial drusen, focusing on safety ...

– Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD – – Broadens global development program for ...

In the Phase 2 S-OLARIS clinical trial in axial spondyloarthritis (axSpA), sonelokimab (SLK) demonstrated clinically ...

Randomized, placebo-controlled study to evaluate safety, tolerability, and potential for positive impact on lung function ...

SALT LAKE CITY, UT, UNITED STATES, January 20, 2026 /EINPresswire.com/ — PhotoPharmics, Inc. today announced the peer-reviewed publication of results from its Phase ...

A randomized phase 2 peri-operative (neoadjuvant plus adjuvant) study of fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) versus anti–PD-1 alone in patients with resectable stage III and IV melanoma ...

Ananda Pharma, a UK-based biopharmaceutical company developing regulatory approved cannabidiol medicines to treat complex, chronic conditions, is pleased ...